Thank you for your considered response, I really appreciate it....

First 25 Last

Share
Profile

Follow
Newbie2015

170 Posts.

56

30/10/22

12:38

Post #: 64480798
Share

Originally posted by Densy: ↑

Hi Newbie and thanks for the reply.

You'll see from that announcement the MRX / MRI detection is preclinical research. I am aware that in preclinical work - including 'phantoms' which are a replica breast - the spions were detectable by both MRX and MRI, and that in mouse models using tumour xenografts and tail-vein spion injections both imaging modalities could detect the spions, which aggregated in the tumour xenografts indicating the targeting ligand was working, too.

What I would like to hear from the company is some clarification in relation to the performance of the HER2 targeting spions - not just that they have the ability to reach the lymph node - and the subsequent detectability of the 'attached' spions using both MRX and MRI in vivo.

This is the first time IBX has been in the clinic and, so far as I can see, we're hearing news about safety and tolerability as well as spion transport to the lymph node, but absolutely nothing about the performance of the product as a diagnostic agent.

While Bob is correct when he says that the company needs to be careful not to jump the gun in proclaiming success, there's also nothing precluding an announcement that: 'In the fist five patients, the HER2 targeting spions were found to have bound to tumour cells and were detectable by both MRI and MRX. While encouraging, these early results do not allow robust conclusions to be drawn and further updates will be provided once the trial's statistical endpoint is known.'

My view is that the need to show caution with trial updates has to be balanced against the need to keep the market informed of progress and to recognise that significant delays in recruitment mean that the current lack of news is seriously testing investor patience, putting huge downward pressure on the SP.

The lack of commentary in relation to product performance needs to be addressed IMO.

Cheers

Densy

Expand

Thank you for your considered response, I really appreciate it. My views are aligned with yours. They really need to address product performance now that they at least have 7 patients and under 3 quarters of cash left. If they do a CR before they release some pretty images , the believers like myself will lose confidence. Surely, they can put caveats and share interim data.

IBX Price at posting: 2.9¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SKS

SKS secures $20M for extension works on Melbourne data centre

LTR

Liontown's first spodumene shipment to leave Kathleen Valley this month – but prices far from 2022

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

There are more pages in this discussion • 7 more messages in this thread...

First 25 Last

Add IBX (ASX) to my watchlist

(20min delay)
Last 3.3¢		Change -0.002(5.71%)		Mkt cap ! $1.176M

Open	High	Low	Value	Volume
3.4¢	3.4¢	3.3¢	$1.459K	42.94K

Buyers (Bids)

No.	Vol.	Price($)
1	9151	3.3¢

Sellers (Offers)

Price($)	Vol.	No.
3.4¢	25398	2

View Market Depth

No.	Vol.	Price($)
1	9151	0.033
1	26188	0.032
2	48878	0.031
4	399274	0.030
1	177000	0.029

Price($)	Vol.	No.
0.034	25398	2
0.036	9093	2
0.040	18227	3
0.044	1422	1
0.045	2730	1

Last trade - 12.05pm 04/09/2024 (20 minute delay)

IBX (ASX) Chart

Thank you for your considered response, I really appreciate it....

SKS secures $20M for extension works on Melbourne data centre

Liontown's first spodumene shipment to leave Kathleen Valley this month – but prices far from 2022

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you for your considered response, I really appreciate it....

Top Stories

SKS secures $20M for extension works on Melbourne data centre

Liontown's first spodumene shipment to leave Kathleen Valley this month – but prices far from 2022

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News